Home › Prostate Cancer › Illinois
Prostate Cancer clinical trials in Illinois
65 studies for Prostate Cancer are looking for participants at sites in Illinois.
Cities in Illinois
- Chicago45 studies
- Cicero15 studies
- Decatur12 studies
- Evanston10 studies
- Naperville10 studies
- Peoria9 studies
- Aurora9 studies
- Champaign8 studies
- Charleston7 studies
- Bloomington7 studies
- Danville7 studies
- Joliet7 studies
- Waukegan7 studies
- North Peoria6 studies
- Springfield6 studies
- Galesburg6 studies
- Arlington Heights4 studies
- Carbondale3 studies
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Alton Memorial Hospital, Alton
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- and 42 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 13, 2026 · NCT04423211Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Northwestern University, Chicago
RecruitingPhase 2
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT05691465Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- and 12 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382WATER IV PCa (AS Sub-study)
- University of Chicago, Chicago
- Endeavor Health, Glenview
Recruiting
Ages 45 and older · Men · Updated Nov 6, 2026 · NCT07650448A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 52 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Carle at The Riverfront, Danville
- and 11 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06632977Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Northwestern University, Chicago
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
- and 9 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT07200830Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- and 31 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT06931340A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- Associated Urological Specialists, Chicago Ridge
RecruitingPhase 2
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT07832292A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- University of Illinois Hospital & Health Sciences System, Chicago
RecruitingPhase 1
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT05800665A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 30, 2026 · NCT06925737Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Oct 29, 2026 · NCT05519449Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Chicago Cancer Center, Zion
RecruitingPhase 1
Ages 18 and older · Men · Updated Oct 27, 2026 · NCT05997615A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
RecruitingPhase 2
Ages 18 and older · Men · Updated Oct 26, 2026 · NCT05593497Precision-Based Genomics in Prostate Cancer
- NorthShore University HealthSystem, Evanston
RecruitingObservational study
Ages 18 to 120 · Men · Updated Oct 26, 2026 · NCT04706663A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Alton Memorial Hospital, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 40 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 23, 2026 · NCT05946213A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Illinois Cancer Care ( Site 0104), Peoria
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06136650A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- University of Illinois Chicago, Chicago
- Cancer Care Specialists of Illinois, Decatur
- Midwestern Regional Medical Center dba City of Hope Chicago, Zion
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 20, 2026 · NCT07213674AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, O'Fallon
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 19, 2026 · NCT07611110A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Research Site, Chicago
RecruitingPhase 1
Ages 18 and older · Men · Updated Oct 16, 2026 · NCT06879041Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Research Site, Chicago
- Research Site, Chicago
- Research Site, Elk Grove Village
- and 1 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 15, 2026 · NCT07711002Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Northwestern University, Chicago
- University of Illinois Cancer Center at Chicago, Chicago
RecruitingPhase 3
Ages 18 to 100 · Men · Updated Oct 15, 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Chicago
- Research Site, Chicago Ridge
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 14, 2026 · NCT06952803This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Associated Urological Specialists - Chicago Ridge, Chicago Ridge
- Cancer Care Specialists of Illinois, Decatur
- Cancer Care Specialists of Illinois, O'Fallon
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 14, 2026 · NCT07028853FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
- Northwestern University, Chicago
- Northwestern Medicine: Kishwaukee, DeKalb
- Northwestern Medicine: Delnor, Geneva
- and 3 more
RecruitingPhase 2
Ages 18 and older · Men · Updated Oct 8, 2026 · NCT06244004Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Rush - Copley Medical Center, Aurora
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- and 18 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 8, 2026 · NCT03678025Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Chicago
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- Northwestern Medicine Chicago Proton Center, Warrenville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 29, 2026 · NCT01492972DESTINY-PANTUMOUR04
- Research Site, Decatur
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- University of Chicago, Chicago
RecruitingPhase 2/3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06780670Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- NorthShore University Health System, Glenbrook Hospital, Glenview
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT06056830A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Associated Urological Specialists, Chicago Ridge
- NorthShore University HealthSystem, Evanston
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 3, 2026 · NCT07005154A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- Endeavor Health, Evanston
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 31, 2026 · NCT05726292A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- University of Chicago, Chicago
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Aug 20, 2026 · NCT06785636PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
- Rush MD Anderson, Chicago
RecruitingPhase 3
Ages 18 and older · Men · Updated Jul 22, 2026 · NCT06274047Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- University of Illinois, Chicago
- Elmhurst Memorial Hospital, Elmhurst
- Edward Hospital/Cancer Center, Naperville
- and 3 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Jul 14, 2026 · NCT06592924Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- Illinois Cancer Specialists, Arlington Heights
- Comprehensive Urologic Care, Lake Barrington
RecruitingPhase 1
Ages 18 and older · Men · Updated Jul 9, 2026 · NCT05413421CARE Tool Study Aim 3
- Alton Memorial Hospital, Alton
Recruiting
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT07296887From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.